Core Viewpoint - Walgreens Boots Alliance, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and unlawful conduct regarding prescription medication dispensing [1][3][4] Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled Klein v. Walgreens Boots Alliance, Inc., and covers stock purchases made between April 2, 2020, and January 16, 2025 [1] - Investors have until March 31, 2025, to seek appointment as lead plaintiff in the lawsuit [1] Allegations Against Walgreens - The lawsuit alleges that Walgreens made false statements and failed to disclose ongoing violations of federal laws related to prescription medication [3] - Specific allegations include the dispensing of unlawful prescriptions and seeking reimbursement from federal health care programs, which led to a significant drop in stock price following the announcement of a civil complaint by the U.S. Department of Justice [4] Impact on Stock Price - Following the DOJ's announcement on January 17, 2025, Walgreens' stock price fell by more than 12% over two trading sessions [4] Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Walgreens stock during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [5] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having recovered $6.6 billion for investors in class action cases, significantly more than any other firm in the last four years [6]

Core Insights - Grubhub has partnered with Walgreens to offer on-demand delivery of 15,000 everyday essential items from Walgreens and Duane Reade locations nationwide [1][2][3] - The collaboration aims to enhance customer experience by broadening access to convenience items, with data indicating that customers who shop from convenience merchants on Grubhub order nearly three times more per month than those who do not [2][3] - Walgreens and Duane Reade are now part of Grubhub+, Grubhub's loyalty program, providing members with benefits such as $0 delivery fees and exclusive offers [3][7] Company Overview - Grubhub is a leading U.S. ordering and delivery marketplace, connecting customers with local restaurants and convenience retailers, featuring 375,000 merchants across over 4,000 U.S. cities [4] - Walgreens, founded in 1901, serves nearly 9 million customers daily through approximately 8,500 stores in the U.S. and Puerto Rico, employing around 220,000 team members [5][6] - Walgreens is part of Walgreens Boots Alliance, Inc., which integrates healthcare, pharmacy, and retail services, with pharmacists playing a crucial role in patient care [6]

Core Viewpoint - Walgreens Boots Alliance, Inc. is facing allegations of issuing materially false and misleading statements regarding its compliance with federal laws governing prescription medication dispensation and reimbursement during the class period from April 2, 2020, to January 16, 2025 [1] Group 1: Allegations and Legal Context - The complaint alleges that Walgreens continued to engage in widespread violations of federal law despite its claims of improved regulatory compliance [1] - The conduct of Walgreens is said to expose the company to increased risks of regulatory scrutiny, civil liability, and reputational harm [1] - Revenues from the sale of prescription medications are claimed to be unsustainable due to their derivation from unlawful conduct [1] Group 2: Shareholder Information - Shareholders who purchased shares of WBA during the specified class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for March 31, 2025 [2] - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2] Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3]

Core Viewpoint - A class action lawsuit has been filed against Walgreens Boots Alliance, Inc. for allegedly misleading investors regarding its distribution of opioid prescriptions and failing to comply with federal regulations [1][2]. Allegations - The lawsuit claims that Walgreens engaged in widespread violations of federal law concerning prescription medication dispensation and reimbursement, despite its stated commitment to regulatory compliance [2]. - It is alleged that Walgreens' revenues from prescription medications were unsustainable due to unlawful conduct, which could lead to increased regulatory scrutiny and civil liability [2]. DOJ Complaint - On January 17, 2025, the Department of Justice (DOJ) filed a civil complaint against Walgreens, alleging that the company knowingly filled millions of illegitimate prescriptions for controlled substances, including excessive quantities of opioids [3]. - The complaint states that Walgreens was aware of its responsibility to maintain compliance and that its business practices contradicted previous commitments to uphold regulatory measures [3]. - Following the DOJ's announcement, Walgreens' stock price dropped by $1.56 per share, a decline of 12.06%, closing at $11.37 per share on January 21, 2025 [3]. Class Action Participation - Shareholders of Walgreens Boots Alliance, Inc. may be eligible to participate in the class action lawsuit, with options to serve as lead plaintiff or remain an absent class member [4].

Core Viewpoint - Walgreens Boots Alliance is experiencing a potential acquisition interest, which has led to a rise in its stock price amid ongoing struggles and challenges faced by the company [1][2][4]. Group 1: Company Performance - Walgreens has been struggling for years, facing issues such as overpayment in the acquisition of VillageMD urgent care centers, opioid lawsuits, and a slowdown in COVID vaccine sales [2]. - The company's market capitalization has fallen to approximately $9.3 billion, making it a potentially attractive acquisition target due to its assets, which include around 10,000 stores in the U.S. [2]. - Despite some signs of recovery with growth in sales and adjusted earnings per share, Walgreens continues to face significant challenges [4]. Group 2: Acquisition Interest - There have been reports of interest from private equity firm Sycamore in acquiring Walgreens, although the likelihood of a deal remains uncertain [3]. - Recent comments from CNBC's David Faber have sparked optimism among investors regarding a potential deal, contributing to a 10.2% increase in stock price [1][3]. - The buyout price from Sycamore is currently unclear, but ongoing rumors are expected to influence Walgreens' stock movement [4].

As per a media report in December, Walgreens Boots Alliance Inc WBA suggested the company is in talks to be acquired by Sycamore Partners.Walgreens's market value has shrunk from over $100 billion a decade ago to around $8.4 billion, as per data from Benzinga Pro.Earlier on Tuesday, citing CNBC, the Bloomberg report noted that the take-private deal with the private equity firm is still possible.Walgreens Boots Alliance' deal appeared "mostly dead a couple of weeks ago," CNBC's David Faber said Tuesday. He s ...

Walgreens Boots Alliance (WBA) , already dealing with a range of challenges, is set to face further market pressures after Moody’s Ratings downgraded its outlook from stable to negative last Friday. The downgrade highlights significant risks tied to the company’s multi-year operational turnaround strategy. The shift comes as the company continues to face a weaker consumer environment, growing inflation and reimbursement rate pressures, along with challenges from legal disputes and dark rent from its planned ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Walgreens Boots Alliance, Inc. common stock between April 2, 2020, and January 16, 2025, of the March 31, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Walgreens common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by March 31, 2025, representing other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been consistently ranked among the top firms for securities class action settlements since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that Walgreens failed to disclose widespread violations of federal law regarding prescription medication dispensation and reimbursement during the Class Period [5]. - It claims that Walgreens' conduct posed a risk of regulatory scrutiny, civil liability, and reputational harm, and that the company's public statements were materially false and misleading [5].

SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) common stock between April 2, 2020 and January 16, 2025, all dates inclusive (the "Class Period"), have until March 31, 2025 to seek appointment as lead plaintiff of the Walgreens class action lawsuit. Captioned Klein v. Walgreens Boots Alliance, Inc., No. 25-cv-01058 (N.D. Ill.), the Walgreens class action lawsuit charges Walgreens as well as certa ...

The most recent trading session ended with Walgreens Boots Alliance (WBA) standing at $9.70, reflecting a -0.51% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss of 0.01%. At the same time, the Dow lost 0.37%, and the tech-heavy Nasdaq gained 0.41%.Shares of the largest U.S. drugstore chain have depreciated by 24.59% over the course of the past month, underperforming the Retail-Wholesale sector's gain of 9.64% and the S&P 500's gain of 4.88%.The upcoming earnings r ...